| Fund Name | Location |
| Altpoint Capital Partners | New York, New York, United States |
| Blue Rock Capital | Delaware, United States, Wilmington |
| Cartesian Capital Group | New York, New York, United States |
| Creative Wings | - |
| GDI Capital | - |
| Great Road Holdings | Harrison, New York, United States |
| Juesheng Investment | China, Hangzhou, Zhejiang |
| Kepha Partners | Massachusetts, United States, Waltham |
| Lamp Post Group | Chattanooga, Tennessee, United States |
| Mondelez International | Deerfield, Illinois, United States |
| Otter Media | California, Santa Monica, United States |
| Qixing Control Equipment | China, Shaanxi, Xian Shi |
| SATUS Starter | Kraków, Malopolskie, Poland |
| SMC Space Ventures | - |
| Tekton Ventures | California, San Francisco, United States |
| Tesla | California, Palo Alto, United States |
| Third Derivative | - |
| Whiteboard Capital | India, Maharashtra, Mumbai |
| Zanichelli Venture | Bologna, Emilia-Romagna, Italy |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Geneoscopy | $105M | 16 Nov 2021 | City of Saint Louis, Missouri, United States | ||
Wugen | $172M | 15 Jul 2021 | St Louis, Missouri, United States | ||
Arch Oncology | $105M | 27 Apr 2021 | California, United States | ||
Mana Therapeutics | $35M | 08 Jan 2021 | Arlington, Virginia, United States | ||
Geneoscopy | $6M | 02 Oct 2019 | City of Saint Louis, Missouri, United States | ||
Arch Oncology | $50M | 25 Mar 2019 | California, United States |
– Arch Oncology, a clinical-stage immuno-oncology company, has closed a $105m Series C financing co-led by Eventide Asset Management, Cowen Healthcare Investments and current investor 3×5 Partners.
– New investors in the round included Adage Capital Management, Point72 Asset Management, Avego Healthcare Capital, FMB Research and Broadfin Holdings.
– The company’s existing investors, including Roche Venture Fund, RiverVest Venture Partners, and Lightchain also participated in the round.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Geneoscopy | $105M | 16 Nov 2021 | City of Saint Louis, Missouri, United States | ||
Wugen | $172M | 15 Jul 2021 | St Louis, Missouri, United States | ||
Arch Oncology | $105M | 27 Apr 2021 | California, United States | ||
Mana Therapeutics | $35M | 08 Jan 2021 | Arlington, Virginia, United States | ||
Geneoscopy | $6M | 02 Oct 2019 | City of Saint Louis, Missouri, United States | ||
Arch Oncology | $50M | 25 Mar 2019 | California, United States |
